Benemid is a small molecule that works as a Solute Carrier Family 22 Member 11 Inhibitor; Solute Carrier Family 22 Member 6 Inhibitor; Solute Carrier Family 22 Member 8 Inhibitor.[2] It is being used across 18 indications, with its most advanced program in Approved.[1]
Benemid is one of 430 small molecule programs targeting Partial Epilepsy. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
1931 competitors in COVID-19
Benemid
Spikevax
Bnt162b2
COVID-19 Vaccine
Biaxin
Singulair
Stivarga
Aimovig
Aldactone
Nexavar
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
BENEMID
NDA NDA007898
Sources
Details